ESMO2016 Cancer Market Commentary: Keytruda’s triumph not the last wo... Despite Keytruda's overwhelming victory, it's not over yet in NSCLC
ESMO2016 Eye on ESMO: Day 1 - Access in spotlight before data deluge Europe's biggest cancer conference ESMO is underway
News Merck makes its move: Keytruda filed for first line lung can... Merck steals a march on rival BMS.
Views & Analysis Promise for combination approach to cancer As immuno-oncology increasingly involves more than one agent for best efficacy, market positioning must take a pan-tumour approach.
Partner Content Partner Content The HNSCC immunotherapy race is on - and it's going to be cl... While improper to compare life saving treatments to buses - the metaphor when it comes to head and neck squamous cell carcinoma (HNSCC) is clear.
Cancer FDA accepts Keytruda head and neck cancer filing Merck's PD-1 inhibitor Keytruda (pembrolizumab) has been accepted for priority review by the FDA in another new setting, head and neck cancer.
Patients Delivering the right behavioural ingredients for the moment,... Lirio's Dr Amy Bucher discusses the risks of the declining trust in healthcare institutions from a behavioural science perspective.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
